Process Patent Protection by Exclusion of Foreign Products under Tariff Act

1935 ◽  
Vol 45 (1) ◽  
pp. 169 ◽  
Keyword(s):  
Patent Protection ◽  
Foreign Products ◽  
Process Patent

Price Comparison between Innovator and Generic Medicines Sold by Community Pharmacies in the State of Penang, Malaysia

2008 ◽  
Vol 6 (1) ◽  
pp. 35-42 ◽  
Author(s):  
Asrul Akmal Shafie ◽  
Mohamed Azmi Hassali
Keyword(s):  
Patent Protection ◽  
Generic Drugs ◽  
The State ◽  
Selling Price ◽  
Generic Medicines ◽  
Cross Sectional ◽  
Foreign Products ◽  
Generic Products ◽  
Collection Form ◽  
The Cost

Generic medicines play a key role in the affordability of pharmaceuticals. This study aims to compare price and to document the actual savings that can be achieved if generics are used by consumers in the state of Penang, Malaysia. This is a cross-sectional pilot study on the price of innovator and generic medicines for the 20 most-used medications in Malaysia. Upon consent, 20 retail pharmacies were conveniently selected. A pre-validated data collection form was used to collect their selling price from the community pharmacist. The analysis was limited to medicines in the same dosage form and dose. Those still under patent protection or combined with other active ingredients were excluded from the study. This study found that most innovator drugs are 27–90 per cent more expensive than generics. Some generic drugs are, however, more expensive than their innovator counterparts (40 per cent higher). Some locally produced generics are also more expensive than foreign products. The current findings suggest that consumers can save up to 90 per cent of the cost of their medication by using generic products. Further investigation is needed to explore the causality of the observed differences in price of products in order to increase their accessibility to the general population.

scholarly journals Process Patent Protection via Analysis of Stable Isotope Ratios

2017 ◽  
Vol 21 (7) ◽  
pp. 956-965
Author(s):  
Anthony D. Sabatelli ◽  
Ann Pearson ◽  
John P. Jasper
Keyword(s):  
Stable Isotope ◽  
Patent Protection ◽  
Isotope Ratios ◽  
Stable Isotope Ratios ◽  
Process Patent

Access to Medicines and Performance of the Indian Pharmaceutical Industry: Examining India’s Experience in the New Patent Regime1

2018 ◽  
Vol 20 (4) ◽  
pp. 411-426
Author(s):  
K. Jafar ◽  
P. Sajna
Keyword(s):  
Patent Protection ◽  
Access To Medicines ◽  
Global Markets ◽  
Public Healthcare ◽  
Engineering Technology ◽  
Pharmaceutical Firms ◽  
Monopoly Pricing ◽  
And Performance ◽  
Process Patent ◽  
Indian Pharmaceutical Industry

The advocates of intellectual property rights project strong patent regime as an effective way to promote research and development (R&D) activities leading to innovation while others argue that they may adversely affect local industries in developing countries and result in monopoly pricing that may compromise on larger interests including public healthcare. The process patent regime has enabled Indian pharmaceutical firms to strengthen their technological capability and performance in domestic and global markets. As the country reintroduced product patent protection in 2005, Indian ‘copycats’ could not follow their reverse engineering technology anymore. Being a developing country and ‘pharmacy of the Global South’, India’s experience offers global dimensions to these debates. This article makes an attempt to reflect on India’s experience with the new patent regime; it looks into the pattern of R&D, trade and trend of product patenting in the pharmaceutical sector and revisits public health concerns.

Analysing Mechanical Systems in Domestic and Foreign CAD Systems

2018 ◽  
pp. 10-17
Author(s):  
V. A. Martynyuk ◽  
V. A. Trudonoshin ◽  
V. G. Fedoruk
Keyword(s):  
Sheet Material ◽  
The Finite Element Method ◽  
Cad Systems ◽  
Cad System ◽  
Software Products ◽  
Foreign Products ◽  
Nonlinear Algebraic Systems ◽  
Software Product ◽  
Pipeline Design ◽  
The Mathematical Model

The article considers applications of foreign CAD-systems in creating the challenging projects at domestic enterprises and design bureaus. As stated in the article "... presently, there is no domestic CAD-system that could completely replace such foreign products as NX, CATIA, Credo". Besides, due to international cooperation in creating the challenging projects (for example, the project to create a modern wide-body aircraft, proposed jointly with China), it makes sense to use the worldwide known and popular CAD systems (the aforementioned NX, CATIA, Credo). Therefore, in the foreseeable future, we will still have to use foreign software products. Of course, there always remains a question of the reliability of the results obtained. Actually, this question is always open regardless of what software product is used - domestic or foreign. This question has been haunting both developers and users of CAD systems for the last 30 to 40 years. But with using domestic systems, it is much easier to identify the cause of inaccurate results and correct the mathematical models used, the methods of numerical integration applied, and the solution of systems of nonlinear algebraic systems. Everything is much more complicated if we use a foreign software product. All advertising conversations that there is a tool to make the detected errors available to the developers, remain only conversations in the real world. It is easily understandable to domestic users, and, especially, to domestic developers of similar software products. The existing development rates and competition for potential buyers dictate a rigid framework of deadlines for releasing all new versions of the product and introducing the latest developments into commercial product, etc. As a result, the known errors migrate from version to version, and many users have accepted it long ago. Especially, this concerns the less popular tools rather than the most popular applications (modules) of a CAD system. For example, in CAD systems, the "Modeling" module where geometric models of designed parts and assembly units are created has been repeatedly crosschecked. But most of the errors are hidden in applications related to the design of parts from sheet material and to the pipeline design, as well as in applications related to the analysis of moving mechanisms and to the strength or gas dynamic analysis by the finite element method.The article gives a concrete example of a moving mechanism in the analysis of which an error was detected using the mathematical model of external influence (a source of speed) in the NX 10.0 system of Siemens.

Study of technological characteristics of the Health in gum® base for chewing gum

2020 ◽  
pp. 18-21
Author(s):  
E. Blynskaya ◽  
S. Tishkov ◽  
V. Bueva ◽  
K. Alekseev ◽  
V. Alekseev ◽  
...  
Keyword(s):  
Dosage Form ◽  
Patent Protection ◽  
Chewing Gum ◽  
Direct Compression ◽  
Technological Properties ◽  
Technological Characteristics ◽  
Chewing Gums

Medicated chewing gum is a convenient dosage form that allows to expand the range of medicines, ensure adherence of patients to the treatment and extend patent protection for well-known names of medicines. This article describes the technological properties of the Health in Gum® chewing gum base, which provides medicinal chewing gums with minimal addition of excipients by direct compression.

The Influence of TRIPS Compliant Patent Laws on Indian Pharmaceutical Industry

2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Rupesh Rastogi ◽  
Virendra Kumar
Keyword(s):  
Pharmaceutical Industry ◽  
Patent Protection ◽  
Uruguay Round ◽  
Pharmaceutical Products ◽  
Trips Agreement ◽  
Patent Law ◽  
Patent Laws ◽  
The Impact ◽  
First Time ◽  
Indian Pharmaceutical Industry

The first legislation in India relating to patents was the Act VI of 1856. The Indian Patents and Design Act, 1911 (Act II of 1911) replaced all the previous Acts. The Act brought patent administration under the management of Controller of Patents for the first time. After Independence, it was felt that the Indian Patents & Designs Act, 1911 was not fulfilling its objective. Various comities were constituted to recommend, framing a patent law which can fulfill the requirement of Indian Industry and people. The Indian Patent Act of 1970 was enacted to achieve the above objectives. The major provisions of the act, provided for process, not the product patents in food, medicines, chemicals with a term of 14 years and 5-7 for chemicals and drugs. The Act enabled Indian citizens to access cheapest medicines in the world and paved a way for exponential growth of Indian Pharmaceutical Industry. TRIPS agreement, which is one of the important results of the Uruguay Round, mandated strong patent protection, especially for pharmaceutical products, thereby allowing the patenting of NCEs, compounds and processes. India is thereby required to meet the minimum standards under the TRIPS Agreement in relation to patents and the pharmaceutical industry. India’s patent legislation must now include provisions for availability of patents for both pharmaceutical products and processes inventions. The present paper examines the impact of change in Indian Patent law on Pharmaceutical Industry.

Sign in / Sign up

Export Citation Format

Share Document